Drug Profile

FCX 013

Alternative Names: FCX-013

Latest Information Update: 08 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Fibrocell Science
Developer Fibrocell Science; Precigen Inc
Class Cell therapies; Fibroblast cell therapies; Gene therapies; Skin disorder therapies
Mechanism of Action Gene transference; Matrix metalloproteinase 1 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Circumscribed scleroderma
New Molecular Entity No

Highest Development Phases

Phase I/II Circumscribed scleroderma

Most Recent Events

24 Jun 2022 Castle Creek Biosciences terminates a phase I/II trial in Circumscribed scleroderma in US due to their own decision (NCT03740724)
23 Mar 2021 Phase-I/II development is ongoing in Circumscribed scleroderma in USA (Intradermal)
03 Feb 2020 Intrexon Corporation is now called Precigen Inc

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com